BioCentury
ARTICLE | Clinical News

ING-1: Phase I

May 28, 2002 7:00 AM UTC

In an open-label, dose-ranging U.S. Phase I trial in 22 patients with advanced adenocarcinomas, dose-limiting adverse events including amylase and lipase elevations and abdominal pains occurred at 1 ...